 Entera Bio Ltd NASDAQ: ENTX shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from the completed Phase 2 clinical trial of EB613 for osteoporosis. The company states that its EB613 is positioned to be the first oral bone-building product to treat osteoporosis patients. 